MedTrace Logo

Tacrolimus Versus Methotrexate as Rescue Therapy for Refractory Inflammatory Bowel Disease

NCT03204136 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2017-06-29

No results posted yet for this study

Summary

Mesalazine, steroid, immunosuppressants and biologic agents are main medical treatments in treating inflammatory bowel diseases. Yet some patients develop severe side effects or initial invalid to conventional therapies. Some studies have already showed that tarcolimus and methotrexate are both effective in inducing and maintaining disease remission. Here we conduct a retrospective study to compare the efficancy of tarcolimus and methotrexate in treating refractory inflammatory bowel diseases as rescue therapy.

Conditions

  • Inflammatory Bowel Diseases

Sponsors & Collaborators

  • Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, China

    lead OTHER_GOV

Principal Investigators

  • Zhihua Ran, MD · Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health；Shanghai Inflammatory Bowel Disease Research Center；Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Shanghai Institute of

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2019-04-01
Completion
2019-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03204136 on ClinicalTrials.gov